Pfizer Inc. (NYSE:PFE) stock is one of the biggest gainers from Donald Trump's surprise victory in the U.S. presidential race on speculation that his term will be less hostile to pharmaceutical and biotech companies.
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the pivotal REFLECTIONS B3271002 study, a comparative safety and efficacy study of PF-05280014 versus Herceptin� (trastuzumab), met its primary endpoint.
Pfizer can claim two things that Gilead can't: Revenue is rising and so are earnings (at least on a non-GAAP basis). The pharmaceutical company still has its own risks, though. Legacy established products continue to drag down overall growth. Sales are ...
If investors are looking for a stable dividend stock with upside, Pfizer Inc. (NYSE:PFE) could be one that fits the bill. The stock currently provides a dividend yield of 3.79% for the Healthcare company.